Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)

Sponsor
Institute of Liver and Biliary Sciences, India (Other)
Overall Status
Recruiting
CT.gov ID
NCT04057287
Collaborator
(none)
670
1
36.4
18.4

Study Details

Study Description

Brief Summary

The study aim to identify the risk factors of liver fibrosis among first degree relatives. This study consists of 2 parts (Cross Sectional and Case Control Study).

Part 1: The first primary objective will be achieved by following study design. Study population: First degree relatives of NRC. Study design: A Cross Sectional Study

Part 2 The second Primary objective will be achieved by following study design. Study design:

A Case Control Study

Study population:

Case: NASH related Cirrhosis patients Control-1: Healthy Control. Control-2: HBV Disease Control Study period: 3 Years

All the patients diagnosed with NASH cirrhosis attending Institute of Liver and Biliary Sciences OPD/IPD will be enrolled. An informed consent will be taken. Complete details of the subject will be taken. The data will be collected on socio-demographic by (socio-demographic questionnaire), alcohol by AUDIT-C (Alcohol Use Disorders Identification Test), Tobacco by FTND (Fagerstrom Test Nicotine Dependence), physical activity by IPAQ (International Physical Activity Questionnaire), Diet by FFQ (Food Frequency Questionnaire), physical measurement & all the comorbidities.

Blood will be collected and analyzed for Platelets, PT/INR, Serum Creatinine, LFT, FBS, HOMA-IR, Lipid Profile, HBsAg, AntiHBs, Anti HBc, Anti HCV, Anti HAV, IgM anti HAV, IgM anti HEV, auto-Immune markers, Ceruloplasmin, Transferrin, S.Ferritin, Alpha1antitrpsin and genetic markers.

The stool will be collected and analyzed for gut microbiota profiling.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

The data will be collected on socio-demographic by (socio-demographic questionnaire), alcohol by AUDIT-C (Alcohol Use Disorders Identification Test), Tobacco by FTND (Fagerstrom Test Nicotine Dependence), physical activity by IPAQ (International Physical Activity Questionnaire), Diet by FFQ (Food Frequency Questionnaire), 24-hour dietary recall method, physical measurement & all the comorbidities.

Blood will be collected and analyzed for CBC, LFT, KFT, PT/INR, FBS, HOMA-IR, Lipid Profile, HBsAg, AntiHBs, Anti HBc, Anti HCV, Anti HAV, IgM anti HAV, IgM anti HEV, auto-Immune markers, Ceruloplasmin, Transferrin, S.Ferritin, Alpha1antitrpsin and genetic markers.

The stool will be collected and analyzed for gut microbiota profiling. Controlled Attenuation Parameter and liver stiffness will be measured by using transient elastography. Ultrasound abdomen will be done First degree relatives of indexed patients will be enrolled. First degree relatives who will not accompanying the indexed subject will be contacted telephonically and will be requested to participate in the study.

The data on first degree relative will be collected on similar parameter as of the indexed patient. This will be a cross sectional study.

For each case, 1 healthy controls will be taken. Healthy Control will be identified from the OPD/IPD of ILBS. Liver transplant donors, hospital volunteers, Blood Donors, healthy attendants who are accompanying other patients of different specialties will be enrolled. An informed consent will be taken. The data will be collected on similar parameter as of the indexed patient. This will be case control study.

We will also have disease control (HBV control) for each case enrolled. Subject suffering from Hepatitis B virus related liver cirrhosis will be included as disease control. For each case, 1 disease control will be included. Disease Control will be identified from the OPD/IPD of ILBS. An informed consent will be taken. The data will be collected on similar parameter as of the indexed patient.

Genetic markers and stool microbiota profiling will be done in 30% of the subsets of sample i.e NASH related Cirrhosis, First Degree Relatives, Healthy Control and HBV Disease control.

Study Design

Study Type:
Observational
Anticipated Enrollment :
670 participants
Observational Model:
Family-Based
Time Perspective:
Cross-Sectional
Official Title:
Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC).
Actual Study Start Date :
Sep 18, 2019
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
NASH related Cirrhosis

Other: No intervention
No intervention

Healthy Controls

Other: No intervention
No intervention

First Degree Relatives of NASH related Cirrhosis

Other: No intervention
No intervention

HBV Disease Control

Other: No intervention
No intervention

Outcome Measures

Primary Outcome Measures

  1. Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and their First Degree Relatives. [Day 0]

  2. Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and Healthy Control group. [Day 0]

  3. Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) & 24 hour dietary recall method between NASH related cirrhosis and their First Degree Relatives. [Day 0]

  4. Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) & 24 hour dietary recall method between NASH related cirrhosis and Healthy Control group [Day 0]

  5. Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and their First Degree Relatives. [Day 0]

  6. Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and Healthy Control group [Day 0]

  7. Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and their 1st degree relatives. [Day 0]

  8. Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and Healthy Control group. [Day 0]

  9. Metabolic syndrome as risk factors between NASH cirrhosis and their First Degree Relatives. [Day 0]

  10. Metabolic syndrome as risk factors between NASH cirrhosis and healthy Control [Day 0]

Secondary Outcome Measures

  1. Proportion of Liver fibrosis among first degree relatives of patients with NASH related Cirrhosis. [Day 0]

  2. Physical activity-related risk factors as assessed using the International Physical Activity Questionnaire (IPAQ) between NASH related cirrhosis and HBV disease control. [Day 0]

  3. Dietary risk factors as captured by Food Frequency Questionnaire (FFQ) and 24 hours dietary recall method between NASH related cirrhosis and HBV disease control. [Day 0]

  4. Difference in microbiota profiling as done by 16s RNA sequencing technique between NASH related cirrhosis and HBV disease control. [Day 0]

  5. Genetic Single Nucleotide Polymorphism (SNP's) and Metabolic parameters in NASH related Cirrhosis patients and HBV disease control. [Day 0]

  6. Metabolic syndrome as risk factors between NASH cirrhosis and HBV Cirrhosis [Day 0]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria for NASH related Cirrhosis (Group 1-Index Case)

  1. Age ≥18 yrs

  2. Diagnosed cases of NASH with Cirrhosis.

Exclusion Criteria for NASH related Cirrhosis (Group 1)

  1. Acute on Chronic Liver Failure

  2. Patients with HBV, HCV, Wilson's, Hemochromatosis, alpha 1 antitrypsin deficiency, primary biliary cirrhosis).

  3. Patient on treatment with amiodarone or methotrexate.

  4. Patient with any malignancies

  5. Patient on chemotherapy

Inclusion Criteria for First Degree Relatives (Group 2)

  1. Age ≥8 yrs

  2. All the first degree relatives of index case.

Exclusion Criteria for First Degree Relatives (Group 2)

  1. Alcohol intake

Inclusion Criteria for Healthy Control (Group 3)

  1. Age ≥18 yrs

  2. Subjects with no history of any known liver disease

  3. Non-Alcoholic

  4. Matched with Age (+/- 5 yrs.) and Gender

Exclusion Criteria for Healthy Control (Group 3)

  1. None

Inclusion Criteria for HBV Disease Control (Group 4)

  1. Age ≥18 yrs

  2. HBV Cirrhosis

  3. Matched with Age (+/- 5 yrs.) and Gender

Exclusion Criteria for HBV Disease Control (Group 4)

  1. Patient with any malignancies

  2. HBV related Liver Fibrosis (≤ F3).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute of Liver and Biliary Sciences New Delhi Delhi India 110070

Sponsors and Collaborators

  • Institute of Liver and Biliary Sciences, India

Investigators

  • Principal Investigator: Dr Ankit Bhardwaj, Masters-CR, Institute of Liver and Biliary Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institute of Liver and Biliary Sciences, India
ClinicalTrials.gov Identifier:
NCT04057287
Other Study ID Numbers:
  • ILBS-NRC-01
First Posted:
Aug 15, 2019
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022